Skip to main content
OpenTrials
Completed

NCT Number: NCT00296764

Characterization of Angelman Syndrome

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demeanor. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over an extended period of time.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rady Children's Hospital San Diego, San Diego, California, United States

Loading trial locations.

About this study

AS is a developmental disorder that affects movement, speech, and social demeanor. The disorder is caused by a deficiency of a maternally transmitted gene and is inherited at birth. Children with AS, however, are often not diagnosed until they are between 3 and 7 years old. Symptoms of AS may include, but are not limited to, functionally severe developmental delay; speech impairments; movement or balance problems; and behavioral uniqueness, including any combination of frequent laughter or smiling, apparent happy demeanor, easily excitable personality, hand flapping movements, and short attention span. There are four molecular variations of AS, but past clinical studies have been inconsistent in highlighting the phenotypic differences between them. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over a period of 5 to 10 years. The study will also attempt to establish genotype-phenotype correlations, which might aid in future clinical care of AS patients.

Participation in this observational study will be limited to current or future patients at one of the five study sites. A clinical evaluation will be performed at baseline, including a general patient history, physical and neurological examinations, a nutritional assessment, neuro-imaging, electroencephalography, laboratory testing, and neurodevelopmental testing. A blood sample or mucosal sample will also be taken at baseline to acquire DNA for potential genetic testing. All assessments except the neuro-imaging, electroencephalography, and blood sampling will be repeated at yearly study visits for as long as funding can be secured. In addition, participants will be photographed and perhaps videotaped on a yearly basis in order to document clinical phenotypes and any neurologic abnormalities. Participants may be followed-up for a total of 10 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Molecular diagnosis of Angelman syndrome OR
  • Meets all major diagnostic criteria for Angelman Syndrome and 3 of the 6 minor criteria:

Major Criteria:

  • Functionally severe developmental delay
  • Speech impairment; none or minimal words used
  • Movement or balance disorder
  • Behavioral uniqueness, frequent laughs/smiling, excitable personality, hand flapping, short attention span

Minor Criteria:

  • Deceleration in head circumference growth (post-natal)
  • Seizures (myoclonic, absence, drop, tonic-clonic)
  • Abnormal EEG (with patterns suggestive of AS, or hypsarrhythmia)
  • Sleep disturbance
  • Attraction to or fascination with water
  • Drooling

Exclusion criteria

  • Does not meet diagnostic criteria for Angelman Syndrome
  • Other medical or genetic disorders (except autism)
  • Born extremely premature

Treatment and study plan

Primary outcomes

  1. medical morbidity

    Time frame: annually

    to characterize the medical problems associated with Angelman syndrome, and to determine the relative prevalence of those problems in the different molecular subclasses of Angelman syndrome

  2. developmental progress

    Time frame: annually

    Assess with a variety of neuropsychological instruments, including Bayley Scales of Infant Development, Vineland Adaptive Behavior Scales, Preschool Language Scale

Secondary outcomes

  1. autism

    Time frame: annually

    Evaluate for autism spectrum disorder using Autism Diagnostic Observation Schedule and Autism Diagnostic Interview-Revised

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Baylor College of Medicine
  • Children's Hospital Medical Center, Cincinnati
  • Greenwood Genetic Center
  • National Center for Research Resources (NCRR)
  • Rady Children's Hospital, San Diego
  • Vanderbilt University Medical Center

Registry information

Official study title

Angelman Syndrome Natural History Study

Important dates

Study start
2006
Primary completion
2014
Study completion
2014
First posted
Feb 27, 2006
Registry last updated
Mar 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.